|
Session 86
Poster Abstracts
New Antiretroviral Agents and Approaches-Clinical Studies
Monday, 1:30 - 3:30 pm
Poster Hall |
| 515 |
Prolonged Coating of CCR5 Lymphocytes by PRO 140, a Humanized CCR5 Monoclonal Antibody for HIV-1 Therapy
WC Olson*, H Doshan, C Zhan, J Mezzatesta, A Assumma, R Czarnecky, J Stavola, P Maddon, A Kremer, and R Israel
Progenics Pharma, Tarrytown, NY, US |
516
 |
A Double-blind Placebo-controlled Study in HIV-1-infected Subjects on the Safety, Pharmacokinetics, and Antiviral Effect of Cyclophilin A targeting DEBIO-025
D Steyn1, D Richman2, C Aeschlimann3, J M Dumont3, P Grosgurin3, B Rosenwirth4, C Loveday5, H Porchet3, V Nicolas3, and Pietro Scalfaro*3
1Univ of the Free State, Bloemfontain, South Africa; 2Univ of California, San Diego, La Jolla, US; 3Debiopharm, Lausanne, Switzerland; 4Biomed Primate Res Ctr, Rijswijk, The Netherlands; and 5Intl Clin Virology Ctr, High Wycombe, UK |
517
|
A Phase I/II Randomized, Double-blind, Placebo-controlled Pilot Study of b-D-2,6-Diaminopurine Dioxolane Vs DAPD + Mycophenolate Mofetil in Treatment-experienced Subjects (ACTG 5165)
David Margolis*1, L Mukherjee2, E Hogg3, C Fletcher4, D Ogata-Arakaki5, T Petersen6, D Rusin7, A Martinez8, E Adams8, J Mellors9, and Adult AIDS Clinical Trials Group A5165 team
1Univ of North Carolina at Chapel Hill, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Social & Sci Systems, Silver Spring, MD, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US; 5Univ of Hawaii, Manoa, US; 6Univ of Texas Southwestern Med Ctr, Dallas, US; 7Frontier Sci & Tech Res Fndn, Amherst, NY, US; 8NIAID, NIH, DHHS, Bethesda, MD, US; and 9Univ of Pittsburgh, PA, US |
518
|
Final 48-Week Safety, Tolerability, and Efficacy of Capravirine + Lopinavir/ritonavir and 2 NRTI in Treatment-experienced Patients
P Hawley1, J Hammond1, Randall Tressler*2, R Ryan1, S Raber1, and M Hodges1
1Pfizer Global R&D, La Jolla, CA, US and 2Pharma Products Group, New York, NY, US |
|
